CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
clofarabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00924443
NCT00924443Phase 2Completed
CompareCT.gov

A Phase II Trial of Clofarabine in Older Patients With Acute Myeloid Leukemia for Whom Intensive Chemotherapy is Not Considered Suitable

Genzyme, a Sanofi Company·interventional·Posted Jun 19, 2009·Updated Apr 1, 2015

In Brief

A Phase 2 clinical trial evaluating clofarabine for Acute Myeloid Leukemia. Completed, enrolled 69 participants across 15 sites in 3 countries.

Detailed Summary

The purpose of the study is to determine if treatment of older patients indicated with untreated Acute Myeloid Leukemia (AML) who are not considered to be suitable for intensive chemotherapy, can effectively be treated with Clofarabine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesIreland, Italy, United Kingdom
CollaboratorsBioenvision

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 19, 2009
Enrollment StartJun 1, 2004
Primary CompletionJun 1, 2006
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.0 years ago

Interventions

clofarabinedrug